IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE Drug Patent Profile
When do Ibuprofen And Phenylephrine Hydrochloride patents expire, and when can generic versions of Ibuprofen And Phenylephrine Hydrochloride launch?
Ibuprofen And Phenylephrine Hydrochloride is a drug marketed by Perrigo R And D and is included in one NDA.
The generic ingredient in IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE is ibuprofen; phenylephrine hydrochloride. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the ibuprofen; phenylephrine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ibuprofen And Phenylephrine Hydrochloride
A generic version of IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE was approved as ibuprofen; phenylephrine hydrochloride by PERRIGO R AND D on July 3rd, 2014.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE?
- What are the global sales for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE?
- What is Average Wholesale Price for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE?
Summary for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 4 |
| DailyMed Link: | IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of North Carolina, Chapel Hill | PHASE4 |
| Ache Laboratorios Farmaceuticos S.A. | Phase 3 |
| Pfizer | Phase 3 |
See all IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE clinical trials
Pharmacology for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE
| Drug Class | Nonsteroidal Anti-inflammatory Drug alpha-1 Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha1-Agonists Cyclooxygenase Inhibitors |
US Patents and Regulatory Information for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perrigo R And D | IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE | ibuprofen; phenylephrine hydrochloride | TABLET;ORAL | 203200-001 | Jul 3, 2014 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Ibuprofen and Phenylephrine Hydrochloride Market Dynamics, FDA Risk, and Financial Trajectory
The ibuprofen and phenylephrine hydrochloride combination is an over-the-counter oral product used for temporary relief of nasal congestion, sinus pressure, headache, fever, and minor aches. Its commercial position is weakening because FDA review concluded that oral phenylephrine is ineffective as a nasal decongestant at the labeled dose. The combination has limited patent protection, substantial generic competition, and a regulatory-driven reformulation risk. Financial exposure is concentrated in branded and private-label cold-and-sinus products rather than in a separately reported pharmaceutical franchise.
What is the ibuprofen and phenylephrine hydrochloride combination?
The product combines:
| Ingredient | Typical OTC role | Typical adult dose in combination products |
|---|---|---|
| Ibuprofen | Analgesic, antipyretic, anti-inflammatory | 200 mg |
| Phenylephrine hydrochloride | Oral nasal decongestant | 10 mg |
The combination is sold under brand, store-brand, and generic labels. Haleon’s Advil Sinus Congestion & Pain is a prominent branded example in the U.S. market. Products can differ by strength, tablet count, labeling, packaging, and whether they are marketed as tablets, caplets, or liquid-filled capsules.
Ibuprofen remains a widely used OTC analgesic. Phenylephrine is the commercial vulnerability because the FDA has determined that the available data do not support its effectiveness as an oral nasal decongestant at the current monograph dose.
What is the FDA status of oral phenylephrine?
FDA’s current position is that oral phenylephrine is not effective as a nasal decongestant at the labeled OTC dose. In September 2023, an FDA advisory committee voted unanimously that available data did not support the efficacy of oral phenylephrine. FDA issued a proposed order in November 2024 to remove oral phenylephrine from the OTC monograph for nasal decongestants. The proposal does not immediately ban products or require an immediate market withdrawal. Products may continue to be sold while the rulemaking process proceeds.
The regulatory distinction is important:
| Issue | Current position |
|---|---|
| Ibuprofen | Remains an accepted OTC analgesic active ingredient |
| Oral phenylephrine | Subject to FDA proposed removal from the OTC nasal-decongestant monograph |
| Existing combination products | May remain marketed during the regulatory process, subject to applicable labeling and manufacturing requirements |
| Long-term labeling | At risk of losing the oral nasal-decongestant indication |
| Combination economics | Dependent on whether manufacturers reformulate, relabel, or discontinue products |
The FDA action affects the decongestant claim, not ibuprofen’s analgesic or antipyretic status. A manufacturer could potentially preserve an ibuprofen product, but it could not continue to market the same oral phenylephrine claim if FDA finalizes the proposed order and establishes an effective compliance date. (FDA, 2023; FDA, 2024)
When could ibuprofen and phenylephrine products lose exclusivity?
The combination has no meaningful modern exclusivity period comparable to a new prescription drug. It is generally sold through the OTC monograph system, where approved active ingredients, doses, indications, labeling, and conditions of use are established by regulation.
There are three distinct forms of exclusivity:
| Exclusivity category | Position for ibuprofen/phenylephrine |
|---|---|
| New-drug exclusivity | Generally not applicable to monograph-compliant products |
| Orange Book patent exclusivity | Usually not the principal barrier for these OTC combinations |
| Brand and trade-dress protection | Can remain commercially relevant but does not block generic entry |
| Retail distribution advantage | Often more important than legal exclusivity |
Generic entry has already occurred. Store brands and private-label products compete on price and retailer placement. The principal commercial protection for branded products is consumer recognition, shelf placement, advertising, packaging, and retailer relationships.
What patents protect ibuprofen and phenylephrine hydrochloride products?
The active ingredients are old and broadly available. Ibuprofen was discovered and commercialized decades ago, while phenylephrine hydrochloride has also been used in OTC products for many years. Core composition-of-matter patent protection is not commercially relevant.
Potential patent categories include:
- Tablet or caplet formulation patents
- Liquid-filled capsule technology
- Modified-release or timed-release formulations
- Manufacturing processes
- Packaging and delivery systems
- Particular dosage combinations
- Method-of-use claims
For standard immediate-release 200 mg ibuprofen/10 mg phenylephrine products, the practical barrier is low. Any surviving formulation patent would need to cover a commercially important product feature and withstand invalidity and noninfringement challenges. Older formulation patents may exist, but they do not create a broad market barrier to ordinary immediate-release generic products.
What is the Orange Book status of the combination?
The FDA Orange Book is principally designed for approved prescription and certain approved nonprescription drug applications. Many OTC monograph products do not have an NDA-based Orange Book listing comparable to prescription products.
For this combination, the relevant competitive framework is usually:
- OTC monograph compliance;
- FDA labeling and ingredient status;
- Trademark and trade-dress rights;
- Formulation-specific patents, if any;
- Manufacturing and retail execution.
An Orange Book patent listing should not be assumed merely because a branded OTC product has a recognizable name. Product-specific NDA and patent status can differ by manufacturer and dosage form. (FDA, 2025a)
How strong is the patent estate for ibuprofen and phenylephrine?
The patent estate is weak as a market-wide barrier and moderate only where a manufacturer owns a narrow, commercially differentiated formulation.
| Patent factor | Assessment |
|---|---|
| Active-ingredient patents | Expired or commercially irrelevant |
| Basic combination claims | Vulnerable to prior-art and obviousness challenges |
| Standard immediate-release tablets | Low protection |
| Specialized delivery systems | Potentially stronger, but product-specific |
| Manufacturing know-how | Can reduce substitution speed without creating legal exclusivity |
| Trade dress and trademarks | Useful against copying of branding, not against generic products |
The likely commercial risk is regulatory displacement rather than patent litigation. FDA’s proposed action against oral phenylephrine could eliminate the product’s principal congestion indication even if no competitor asserts a patent.
How does the combination compare with competing cold-and-sinus drugs?
The product competes across two distinct dimensions: pain relief and decongestion.
| Product type | Analgesic | Decongestant | Key commercial issue |
|---|---|---|---|
| Ibuprofen/phenylephrine | Ibuprofen | Oral phenylephrine | FDA efficacy and future labeling risk |
| Acetaminophen/phenylephrine | Acetaminophen | Oral phenylephrine | Same phenylephrine exposure |
| Ibuprofen/pseudoephedrine | Ibuprofen | Pseudoephedrine | Stronger decongestant positioning but retail restrictions |
| Acetaminophen/pseudoephedrine | Acetaminophen | Pseudoephedrine | Established alternative with purchase controls |
| Ibuprofen alone | Ibuprofen | None | Lower regulatory risk but narrower indication |
| Acetaminophen alone | Acetaminophen | None | Large, established pain-relief category |
Pseudoephedrine products may benefit from the weakness of oral phenylephrine, but they face purchase restrictions under the Combat Methamphetamine Epidemic Act and state-level controls. Those restrictions affect convenience, inventory handling, and retailer participation. A manufacturer replacing phenylephrine with pseudoephedrine may improve efficacy positioning but increase operational and compliance costs.
What market dynamics are affecting sales?
The combination is exposed to four market forces.
FDA-driven product substitution
Retailers and manufacturers may reduce purchases of products containing oral phenylephrine before FDA completes its rulemaking. The risk is greatest for products whose value proposition depends on congestion relief rather than pain relief.
Private-label pricing
Store brands and generic manufacturers can sell comparable products at lower prices. The active ingredients are inexpensive, and the product does not require a complex biological manufacturing platform. Retailer bargaining power can compress branded gross margins.
Seasonal demand
Sales are concentrated in the fall and winter respiratory season. Demand is affected by influenza, respiratory syncytial virus, common-cold activity, consumer travel, and weather. This creates inventory and forecasting risk, especially if FDA developments occur before the peak season.
Consumer migration
Consumers seeking congestion relief may move toward pseudoephedrine products, topical nasal decongestants, saline products, or nonpharmacologic treatments. Consumers seeking pain relief may shift to standalone ibuprofen or acetaminophen.
What is the financial trajectory for manufacturers?
Public companies generally do not report revenue for the ibuprofen/phenylephrine combination as a standalone product. Financial analysis therefore requires a category-based model rather than a product-level revenue series.
The likely trajectory is:
| Period | Financial direction | Main driver |
|---|---|---|
| Near term | Stable to modestly negative | Existing inventory, continued legal sale, seasonal demand |
| Regulatory transition | Negative for phenylephrine combinations | Delisting, relabeling, retailer caution, consumer uncertainty |
| Post-reformulation | Mixed | Ibuprofen brand retention versus loss of congestion claim |
| Long term | Lower product-specific revenue | Substitution by pseudoephedrine, standalone analgesics, or new formulations |
For a branded manufacturer, the key financial exposures are:
- Lost units of phenylephrine-containing products;
- Retailer delistings or reduced shelf allocation;
- Packaging write-offs;
- Reformulation and regulatory expenses;
- Advertising costs for replacement products;
- Cannibalization by the manufacturer’s own ibuprofen or pseudoephedrine products;
- Potential loss of premium pricing versus private-label products.
Haleon identifies Advil and other consumer-health brands as material products within its portfolio, but public reporting does not isolate revenue for Advil Sinus Congestion & Pain or the ibuprofen/phenylephrine combination. Therefore, any precise product-level revenue estimate would be unsupported by public company disclosures. (Haleon, 2025)
What formulation patents and manufacturing barriers matter?
The active ingredients are relatively easy to source, and immediate-release tablets are straightforward to manufacture at scale. The main technical barriers are commercial execution and quality control.
Relevant manufacturing considerations include:
- Uniform distribution of low-dose phenylephrine;
- Tablet hardness and dissolution performance;
- Stability under humidity and temperature variation;
- Compatibility of ibuprofen with excipients;
- Packaging controls for shelf life;
- Consistent content uniformity;
- Rapid relabeling if the decongestant indication changes.
Formulation know-how can support supply reliability and product quality, but it is unlikely to prevent generic substitution. A manufacturer with an integrated OTC supply chain can respond faster to FDA developments and retailer demands than a smaller supplier.
Are Paragraph IV challenges relevant?
Paragraph IV litigation is generally not the central pathway for ordinary monograph-compliant OTC products. Paragraph IV challenges apply to patents listed for approved drug applications, mainly under the Hatch-Waxman framework. Standard ibuprofen/phenylephrine products usually compete without a modern patent barrier requiring a paragraph IV filing.
Paragraph IV exposure could arise if a specific product is marketed under an NDA with listed patents covering a formulation, dosage form, or manufacturing process. That would require product-specific review of the FDA application and Orange Book listings. The broad combination category should not be treated as paragraph IV-protected.
Which companies are challenging the market leaders?
The competitive challenge is fragmented rather than concentrated in one branded rival.
Key participants include:
- Haleon, through Advil-branded sinus and cold products;
- Perrigo, through store-brand and private-label OTC products;
- Kenvue, through Tylenol and related cold products;
- Reckitt, through Mucinex and other respiratory products;
- Retail pharmacy chains and mass merchants selling private-label equivalents;
- Generic manufacturers supplying tablets, caplets, and liquid-filled formats.
The most consequential competitors may be retailers because they can replace a branded product with a private-label equivalent while preserving shelf space and category sales.
What litigation and settlement agreements affect the product?
No broad, category-defining patent litigation or settlement agreement is central to the ibuprofen/phenylephrine market. The primary legal issue is FDA administrative action concerning oral phenylephrine.
Potential litigation could arise from:
- Challenges to FDA’s final monograph decision;
- Consumer claims concerning efficacy representations;
- False-advertising disputes;
- Trademark or trade-dress copying;
- Product-liability claims involving ibuprofen adverse events;
- Contract disputes over private-label supply.
These risks are distinct from patent litigation. The FDA process is more likely to affect revenue than a generic patent settlement.
What generic launch scenarios exist?
Three launch scenarios are commercially plausible.
Scenario 1: Continued sale during FDA review
Manufacturers continue selling existing products, but retailers reduce forward inventory. Branded products retain seasonal demand, while generic prices remain under pressure.
Scenario 2: Phenylephrine claim removal
Manufacturers relabel or discontinue the combination. Ibuprofen-only products may retain pain and fever demand, but the product loses its congestion-related premium and consumer relevance.
Scenario 3: Shift to pseudoephedrine combinations
Manufacturers migrate toward ibuprofen/pseudoephedrine products. This may preserve the dual-symptom proposition but introduces purchase controls, behind-the-counter handling, and state compliance costs.
The most exposed products are those whose packaging, advertising, and consumer recognition depend heavily on "sinus congestion" relief.
What geographic coverage matters?
The FDA action is U.S.-specific. Other jurisdictions may maintain different positions on oral phenylephrine, impose different monograph requirements, or permit different combinations and claims.
| Region | Commercial implication |
|---|---|
| United States | Highest immediate regulatory risk from FDA proposed removal |
| Canada | Separate Health Canada review and labeling framework |
| European Union | National and EU-level OTC requirements vary by product and indication |
| Latin America | Market access and labeling rules vary widely |
| Asia-Pacific | Local registration, monograph, and combination rules determine availability |
A multinational manufacturer cannot assume that a U.S. reformulation automatically applies globally. However, global packaging simplification and supply-chain consolidation may encourage harmonized changes.
Key Takeaways
- Ibuprofen remains commercially strong as an OTC analgesic.
- Oral phenylephrine is the principal weakness in the combination.
- FDA’s proposed removal of oral phenylephrine from the OTC monograph creates material relabeling and discontinuation risk.
- The combination has limited practical patent protection and faces established generic competition.
- Orange Book and Paragraph IV issues are usually secondary to monograph compliance, trademarks, formulation rights, and FDA rulemaking.
- Public companies do not generally disclose standalone revenue for ibuprofen/phenylephrine products.
- The most likely financial outcome is pressure on phenylephrine-containing products, followed by migration toward ibuprofen alone, pseudoephedrine combinations, or alternative congestion products.
- Retailers and private-label suppliers have significant negotiating power because manufacturing complexity is relatively low.
FAQs
Is ibuprofen and phenylephrine hydrochloride being discontinued?
Not immediately. FDA proposed removing oral phenylephrine from the OTC monograph, but products may continue to be marketed during the regulatory process. Final timing depends on FDA’s final order and compliance requirements.
Does the FDA action affect ibuprofen?
No. The action concerns oral phenylephrine’s use as a nasal decongestant. Ibuprofen remains an accepted OTC analgesic, antipyretic, and anti-inflammatory ingredient.
Is Advil Sinus Congestion and Pain protected by patents?
The product category has limited practical patent protection. Any active formulation patent would be product-specific and would not prevent generic manufacturers from selling ordinary ibuprofen/phenylephrine products outside the protected claims.
Will pseudoephedrine replace phenylephrine in cold medicines?
Pseudoephedrine is a likely substitute for some products because it has stronger accepted decongestant positioning. Its use is constrained by federal purchase controls, retailer procedures, and state restrictions.
Is there a separate stock-market investment case for this combination?
Usually not. Manufacturers report broader consumer-health segments rather than standalone combination-product revenue. Investment analysis should focus on portfolio exposure, brand strength, OTC category growth, reformulation costs, retailer relationships, and the company’s ability to shift consumers to replacement products.
References
-
Food and Drug Administration. (2023). Nonprescription drugs advisory committee meeting: Oral phenylephrine efficacy discussion. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Proposal to remove oral phenylephrine from the OTC monograph. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
Haleon plc. (2025). Annual report 2024. Haleon plc.
-
U.S. Food and Drug Administration. (2025b). Over-the-counter monograph drug products. U.S. Department of Health and Human Services.
More… ↓

